Journal of Cardiovascular Disease Research
ISSN: 0975-3583,0976-2833 VOL 16, ISSUE 12, 2025

DEVELOPMENT OF DILTIAZEM-LOADED INTERPENETRATING CROSS-LINKED MICROSPHERES FOR CONTROLLED DRUG DELIVERY: A COMPREHENSIVE REVIEW ON ALOE VERA GEL, DILTIAZEM HCL, AND SODIUM ALGINATE-BASED SYSTEMS

[1]Sandeep Kumar
Faculty of Pharmaceutical Science Rama University
Email: Pals1750@gmail.com
[2]Mr. Akhilesh Kumar*
Assistant Professor, Faculty of Pharmaceutical Science Rama University Kanpur
Email: chemist.akp22@gmail.com

ABSTRACT

Diltiazem hydrochloride (DH) is a widely prescribed non-dihydropyridine calcium channel blocker indicated for the management of hypertension, chronic stable angina, and supraventricular arrhythmias. Despite its clinical efficacy, the conventional immediate-release formulation necessitates administration three to four times daily due to its short plasma elimination half-life of approximately 3.0 to 4.5 hours and extensive first-pass hepatic metabolism, resulting in poor patient adherence and fluctuating plasma concentrations. The development of interpenetrating polymer network (IPN) microspheres represents a promising strategy to overcome these pharmacokinetic limitations by enabling controlled, sustained, and site-specific drug release.

This review comprehensively examines the development of diltiazem-loaded interpenetrating cross-linked microspheres utilizing sodium alginate and Aloe vera gel as the primary polymeric constituents. Sodium alginate, a natural anionic polysaccharide derived from brown seaweed, offers excellent biocompatibility, mucoadhesive properties, and pH-sensitive behavior, making it an ideal candidate for gastrointestinal drug delivery. Aloe vera gel, rich in acemannan and other bioactive polysaccharides, contributes additional mucoadhesive, anti-inflammatory, and wound-healing properties while enhancing the structural integrity of the hydrogel matrix. The combination of these natural polymers through chemical cross-linking with glutaraldehyde and ionotropic gelation with calcium chloride yields a robust IPN architecture capable of modulating drug release over extended periods.

The review discusses the phytochemical and physicochemical properties of the constituent polymers, the mechanisms of IPN formation, formulation variables, characterization methodologies, in vitro release kinetics, and potential clinical applications. Furthermore, future perspectives on optimizing these systems for personalized cardiovascular therapy are explored. The findings suggest that diltiazem-loaded IPN microspheres based on sodium alginate and Aloe vera gel offer a viable platform for improving therapeutic outcomes through enhanced bioavailability, reduced dosing frequency, and improved patient compliance.

Keywords: *Diltiazem HCl, interpenetrating polymer network, microspheres, sodium alginate, Aloe vera gel, controlled release, cross-linking, hydrogel, cardiovascular drug delivery*

1. INTRODUCTION

Controlled drug delivery systems have revolutionized modern pharmaceutical sciences by enabling the administration of therapeutic agents at predetermined rates for predefined periods, thereby maintaining plasma drug concentrations within the therapeutic window while minimizing adverse effects associated with peak-and-trough fluctuations [1]. Among the various controlled-release platforms investigated, polymeric microspheres have garnered significant attention due to their ability to encapsulate both hydrophilic and hydrophobic drugs, protect active pharmaceutical ingredients (APIs) from environmental degradation, and achieve targeted or sustained release profiles through rational material selection and engineering [2,3].

The interpenetrating polymer network (IPN) approach represents a particularly versatile strategy for fabricating advanced drug delivery microspheres. IPNs are defined as combinations of two or more polymers in network form, synthesized in juxtaposition, where at least one polymer is cross-linked in the immediate presence of the other without any covalent bonds between them [4]. This architectural arrangement imparts unique physicochemical properties, including enhanced mechanical strength, improved swelling control, stimuli-responsive behavior, and superior drug-loading capacity compared to single-polymer networks [5].

Natural polysaccharides have emerged as preferred materials for constructing IPN-based drug delivery systems due to their inherent biocompatibility, biodegradability, non-toxicity, and abundance. Sodium alginate, extracted from the

cell walls of brown algae (Phaeophyceae), and Aloe vera gel, obtained from the inner leaf parenchyma of Aloe barbadensis Miller, exemplify two such polysaccharides with complementary pharmaceutical functionalities [6,7]. Sodium alginate forms hydrogels through ionotropic gelation with multivalent cations, exhibiting pH-dependent swelling behavior that is particularly advantageous for oral drug delivery. Aloe vera gel, conversely, is rich in acemannan (a mannose-rich polysaccharide), vitamins, minerals, and enzymes that confer anti-inflammatory, antimicrobial, and tissue-regenerative properties [8].

This review focuses specifically on the convergence of these materials into IPN microsphere architectures for the controlled delivery of diltiazem hydrochloride. By systematically analyzing the formulation principles, characterization methodologies, release mechanisms, and therapeutic implications, this article aims to provide a comprehensive resource for researchers and formulation scientists working toward the development of next-generation cardiovascular therapeutics.

2. DILTIAZEM HYDROCHLORIDE: PHARMACOLOGICAL PROFILE AND CLINICAL NEED

2.1 Chemical and Pharmacological Properties

Diltiazem hydrochloride ($C_{22}H_{26}N_2O_4S \cdot HCl$; molecular weight 450.98 g/mol) is a benzothiazepine derivative classified as a non-dihydropyridine calcium channel blocker (CCB). Unlike dihydropyridine agents such as nifedipine and amlodipine, diltiazem exhibits both vascular selectivity and direct cardiac effects, functioning as a negative inotrope, negative chronotrope, and negative dromotrope [9]. Its primary mechanism of action involves the inhibition of L-type voltage-gated calcium channels (Cav1.2) in vascular smooth muscle and cardiac myocytes, thereby reducing calcium ion influx during depolarization and promoting smooth muscle relaxation, arterial vasodilation, and decreased myocardial oxygen demand [10].

The United States Food and Drug Administration (FDA) has approved diltiazem for the treatment of chronic stable angina, angina due to coronary artery spasm (Prinzmetal's or variant angina), hypertension, paroxysmal supraventricular tachycardia, and atrial fibrillation with rapid ventricular response [11]. Additionally, numerous off-label applications have been documented, including migraine prophylaxis, treatment of anal fissures, and management of Group 1 pulmonary hypertension in patients demonstrating positive vasoreactivity testing [12,13].

2.2 Pharmacokinetic Limitations and the Rationale for Controlled Release

Despite its broad therapeutic utility, diltiazem hydrochloride presents significant pharmacokinetic challenges that limit the efficacy of conventional immediate-release (IR) formulations. Following oral administration, diltiazem is rapidly and extensively absorbed from the gastrointestinal tract; however, its absolute bioavailability is limited to approximately 40% due to extensive first-pass hepatic metabolism mediated primarily by the cytochrome P450 enzyme CYP3A4 [14]. The plasma elimination half-life ranges from 3.0 to 4.5 hours for immediate-release formulations, necessitating administration three to four times daily to maintain therapeutic plasma concentrations within the recommended range of 50–200 ng/mL [15].

This frequent dosing regimen poses several clinical disadvantages. Fluctuating plasma concentrations contribute to inconsistent therapeutic effects, increased incidence of adverse events during peak concentration phases (including bradycardia, hypotension, peripheral edema, and dizziness), and suboptimal blood pressure control during trough periods [16]. Furthermore, polypharmacy burden and complex dosing schedules significantly compromise patient adherence, particularly among elderly populations with multiple comorbidities who constitute the primary demographic for antihypertensive therapy [17].

The pharmacokinetic profile of diltiazem also exhibits considerable interindividual variability attributable to genetic polymorphisms in CYP3A4 expression, concurrent medications, hepatic function, and formulation-dependent absorption rates [18]. Extended-release (ER) and modified-release (MR) formulations have been developed to mitigate these challenges, with commercial products including Cardizem CD, Cardizem LA, Cartia XT, Tiazac, and

Dilacor XR achieving sustained plasma levels over 12–24 hours and enabling once- or twice-daily administration [19]. However, these conventional ER technologies often rely on synthetic polymers (e.g., Eudragit, ethylcellulose) or osmotic pump mechanisms that may be associated with higher manufacturing costs, limited biocompatibility, and environmental concerns. Natural polymer-based IPN microspheres offer an attractive alternative platform that aligns with the growing emphasis on green pharmacy and sustainable pharmaceutical manufacturing [20].

2.3 Comparative Pharmacokinetic Parameters

Table 1: Pharmacokinetic parameters of diltiazem hydrochloride following oral administration [14,15,21].

Pharmacokinetic Parameter	Value
Oral bioavailability	~40% (due to extensive first-pass metabolism)
Plasma protein binding	70–80%
Elimination half-life (IR)	3.0–4.5 hours
Elimination half-life (ER)	5–10 hours
Time to peak concentration (tmax)	11–18 hours (ER formulation)
Therapeutic plasma concentration	50–200 ng/mL
Volume of distribution	~305 L
Renal excretion (unchanged)	2–4%
Metabolic pathway	CYP3A4 (hepatic)

3. SODIUM ALGINATE AS A NATURAL POLYMERIC CARRIER

3.1 Source, Structure, and Properties

Sodium alginate is a naturally occurring, linear, unbranched anionic polysaccharide extracted primarily from the cell walls of brown seaweed species including Laminaria hyperborea, Macrocystis pyrifera, and Ascophyllum nodosum [22]. Chemically, it is a copolymer composed of β-D-mannuronic acid (M) and α-L-guluronic acid (G) residues arranged in varying sequences along the polymer chain (MMMM, GGGG, or alternating MG blocks) [23]. The molecular weight of commercial sodium alginate preparations typically ranges from 32,000 to 400,000 g/mol, with the ratio of mannuronic to guluronic acid (M/G ratio) significantly influencing the physicochemical properties, including viscosity, gel strength, and swelling behavior [24].

The guluronic acid residues possess a distinctive structural conformation that enables selective binding with multivalent cations, particularly calcium (Ca^{2+}), through the well-known "egg-box" model proposed by Grant et al. [25]. In this model, divalent cations nest within electronegative cavities formed by the spatial arrangement of guluronate blocks, creating ionic cross-links between adjacent polymer chains. This ionotropic gelation mechanism proceeds under exceptionally mild conditions (room temperature, aqueous environment, neutral pH), making it highly suitable for encapsulating heat-sensitive and bioactive molecules including proteins, peptides, and nucleic acids [26].

Sodium alginate exhibits several properties that render it particularly advantageous for oral drug delivery applications. The polysaccharide remains largely insoluble in acidic gastric fluid (pH 1.2–2.5), preserving the integrity of the delivery system during gastric transit. Upon reaching the intestinal environment (pH 6.8–7.4), the carboxylate groups on the polymer backbone undergo deprotonation, increasing electrostatic repulsion between polymer chains and promoting hydrogel swelling [27]. This pH-responsive behavior facilitates targeted drug release in the intestinal tract while protecting acid-labile drugs from gastric degradation. Additionally, sodium alginate demonstrates excellent mucoadhesive properties attributable to electrostatic interactions with the negatively charged mucus glycoproteins, potentially prolonging gastrointestinal residence time and enhancing drug absorption [28].

3.2 Alginate-Based Microspheres in Drug Delivery

The application of sodium alginate in microsphere-based drug delivery has been extensively investigated across diverse therapeutic categories. Tareq et al. [29] developed semi-interpenetrating microspheres using a natural polymer blend of sodium alginate and gelatin, stabilized with glutaraldehyde, for sustained diltiazem release. These systems demonstrated sustained drug release over 24 hours with efficiencies of 82.1% in acidic medium and 63.1% in neutral medium, following first-order and Higuchi kinetics. Microspheres with an alginate-to-gelatin ratio of 80:20 exhibited optimal swelling and diffusion-controlled behavior.

In another study, Maestrelli et al. [30] employed a freeze-drying method to fabricate alginate microspheres encapsulating metformin for oral administration. In vitro release kinetics demonstrated reduced burst release and sustained metformin release in simulated intestinal fluid compared to gastric fluid. Oral administration of the metformin-loaded microspheres to diabetic rats showed excellent glycemic control for up to 8 hours, significantly longer than free metformin. Similarly, Shahnia [31] utilized ionotropic gelation to develop curcumin-loaded alginate microparticles, which displayed sustained release kinetics and improved wound healing potency in animal models.

The versatility of alginate-based microspheres extends to floating gastroretentive systems. Giri et al. [32] developed cross-linked biodegradable hydrogel floating beads using sodium alginate for stomach-site-specific controlled delivery of metronidazole. These systems leveraged the low density of the alginate matrix combined with entrapped air or oil to achieve buoyancy in gastric fluid, extending residence time and enhancing localized drug delivery. Such findings underscore the adaptability of sodium alginate across diverse formulation strategies and therapeutic objectives.

4. ALOE VERA GEL: PHYTOCHEMICAL COMPOSITION AND PHARMACEUTICAL POTENTIAL

4.1 Botanical Origin and Chemical Constituents

Aloe vera (Aloe barbadensis Miller), a succulent plant belonging to the Liliaceae family, has been utilized for medicinal purposes across diverse civilizations for over 3,500 years [33]. The plant produces two distinct exudates: the yellow latex (aloe juice) containing anthraquinones such as aloin and emodin, which possess potent laxative and antimicrobial properties, and the clear, viscous gel (aloe gel) extracted from the inner leaf parenchyma, which serves as the primary material for pharmaceutical and cosmetic applications [34].

The dry matter of Aloe vera gel comprises approximately 55% polysaccharides, 17% sugars, 16% minerals, 7% proteins, 4% lipids, and 1% phenolic compounds [35]. The most pharmacologically significant polysaccharide is acemannan (also known as acetylated mannan or aloe polysaccharide), a linear chain of β-(1,4)-linked mannose residues with acetyl substituents that confer unique physicochemical and biological properties [36]. Acemannan has been extensively studied for its immunomodulatory, antiviral, antitumor, and wound-healing activities. Additional constituents include glucomannan, galactan, arabinan, cellulose, pectin, along with a rich complement of vitamins (A, C, E, B12, folic acid), minerals (calcium, magnesium, zinc, selenium), enzymes (amylase, lipase, alkaline phosphatase), and amino acids [37].

The rheological properties of Aloe vera gel are particularly relevant to its pharmaceutical applications. The gel exhibits pseudoplastic (shear-thinning) flow behavior, with viscosity decreasing under applied shear stress—a property that facilitates processing, spreading, and injectability while maintaining structural integrity at rest [38]. The high water content (>98%) contributes to exceptional hydration capacity, creating a moist environment conducive to wound healing and enabling sustained release of incorporated therapeutic agents through diffusion and matrix erosion mechanisms [39].

4.2 Biological Activities and Therapeutic Properties

Aloe vera gel exhibits a broad spectrum of biological activities that enhance its value as a pharmaceutical excipient and active ingredient. The gel demonstrates significant anti-inflammatory activity through the inhibition of

prostaglandin synthesis, thromboxane A2 formation, and leukocyte infiltration at sites of tissue injury [40]. These anti-inflammatory properties are particularly relevant when formulating diltiazem for conditions such as anal fissures or topical wound healing applications where localized inflammation contributes to patient discomfort and delayed recovery.

The antimicrobial efficacy of Aloe vera gel against common wound pathogens including Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, and Candida albicans has been well-documented [41]. This antimicrobial action is attributed to the synergistic effects of anthraquinones, saponins, and phenolic compounds that disrupt microbial cell membranes and inhibit protein synthesis. When incorporated into drug delivery matrices, these properties may help prevent secondary infections at administration or application sites, particularly for transdermal, buccal, or wound-dressing formulations [42].

Perhaps most importantly for tissue-engineering and regenerative applications, Aloe vera gel significantly accelerates wound healing through multiple mechanisms: stimulation of fibroblast proliferation and collagen synthesis, enhancement of angiogenesis, modulation of growth factor expression (particularly transforming growth factor-β and vascular endothelial growth factor), and promotion of epithelialization [43]. The gel's ability to stimulate macrophage activity and modulate cytokine production further contributes to its immunomodulatory profile [44]. When incorporated into IPN microspheres alongside conventional drugs, these bioactive properties may provide synergistic therapeutic benefits extending beyond the primary pharmacological action of the encapsulated API.

4.3 Aloe Vera in Hydrogel and Microsphere Formulations

The incorporation of Aloe vera gel into polymeric hydrogels and microspheres has been investigated as a strategy to enhance biocompatibility, introduce bioactive functionality, and modulate drug release kinetics. Nabipour and Rohani [45] reported the development of a zirconium metal-organic framework/Aloe vera carrier loaded with naproxen as a versatile platform for drug delivery, demonstrating that the polysaccharide matrix improved drug dispersion and sustained release characteristics. Dadashzadeh et al. [46] developed hybrid alginate/gelatin hydrogels incorporated with niosomal Aloe vera for sustained release as potential skin wound dressings, showing enhanced healing outcomes compared to control formulations.

Novel sodium alginate/poly(vinyl alcohol) hydrogel dressing films enriched with Aloe vera were developed by a simple casting method [47]. The influence of different amounts (5–25%, v/v) of Aloe vera solution on the chemical structure and properties of the hydrogel films was systematically studied. Structural, morphological, mechanical, and thermal characterization confirmed that rigid and thermally stable three-dimensional structures were obtained. The results regarding the release profile of polysaccharides from the hydrogel matrix showed that the active substance was released in a prolonged, gradual manner for over one week. In vitro experiments on normal human dermal fibroblasts showed very good cell attachment to Aloe vera hydrogel discs, which promoted cell spreading and proliferation [48]. These findings collectively support the rationale for incorporating Aloe vera gel into alginate-based IPN microspheres for diltiazem delivery, suggesting the potential for enhanced biocompatibility, extended release duration, and auxiliary therapeutic benefits.

5. INTERPENETRATING POLYMER NETWORK (IPN) MICROSPHERES

5.1 Concept, Classification, and Structural Features

Interpenetrating polymer networks (IPNs) are defined as intimate combinations of two or more cross-linked polymers, at least one of which is synthesized and/or cross-linked in the immediate presence of the other, with no covalent bonds between the constituent networks [49]. This definition, originally proposed by Sperling and co-workers, distinguishes IPNs from simple polymer blends, graft copolymers, and block copolymers based on the topological arrangement of the constituent networks. The resulting materials exhibit properties that typically surpass those of the individual components, including enhanced mechanical strength, improved phase stability, controlled swelling behavior, and tunable permeability [50].

IPNs are broadly classified into several categories based on their synthesis methodology and structural characteristics. Sequential IPNs are formed by first synthesizing Network I, subsequently swelling it with the monomer and cross-linker of Network II, and finally polymerizing Network II in situ. Simultaneous IPNs involve the concurrent polymerization of two independent monomer/cross-linker systems through orthogonal reaction mechanisms (e.g., step-growth and chain-growth polymerizations). Semi-IPNs contain one cross-linked polymer and one linear polymer that interpenetrate without chemical bonding. Full IPNs, conversely, comprise two independently cross-linked networks [51]. For drug delivery applications, semi-IPNs and full IPNs prepared from natural polysaccharides have attracted particular interest due to their biocompatibility, stimuli-responsive behavior, and capacity for controlled drug encapsulation.

The structural features of IPN microspheres confer several advantages for controlled drug delivery. The interlocked network topology restricts chain mobility and prevents macroscopic phase separation, ensuring uniform drug distribution and consistent release kinetics. The dual-network architecture enables independent tuning of each polymer's contribution to the overall material properties: one network may provide mechanical strength and structural integrity, while the other may dominate swelling behavior, mucoadhesion, or biodegradation [52]. Furthermore, the presence of two distinct polymers with different chemical functionalities can impart multi-stimuli responsiveness (e.g., pH, temperature, ionic strength), enabling sophisticated triggered or modulated release profiles tailored to specific physiological environments [53].

5.2 Natural Polymer-Based IPN Microspheres for Drug Delivery

The application of IPN microspheres in drug delivery has expanded significantly over the past two decades, with natural polymers assuming prominence due to their favorable safety profiles and environmental sustainability. Ray et al. [54] developed novel IPN microspheres of xanthan gum and poly(vinyl alcohol) for intestinal delivery of diclofenac sodium. The microspheres, prepared by emulsion cross-linking with glutaraldehyde, achieved drug encapsulation efficiencies up to 82.94% with mean particle sizes ranging from 310 to 477 μm. In vitro release studies demonstrated Fickian diffusion kinetics dependent on the extent of cross-linking and the xanthan gum-to-PVA ratio, with optimal formulations providing controlled release over 12 hours.

Kulkarni et al. [55] synthesized pH-responsive IPN hydrogel beads of poly(acrylamide)-g-carrageenan and sodium alginate for intestinal targeted drug delivery. The beads exhibited pronounced pH-dependent swelling, with minimal hydration at gastric pH (1.2) and extensive swelling at intestinal pH (6.8–7.4). This selective swelling behavior protected encapsulated drugs from gastric degradation while promoting release in the intestinal environment. In vivo evaluation in rabbits confirmed prolonged drug residence time and enhanced bioavailability compared to conventional dosage forms.

The application of IPN microspheres to antihypertensive therapy has shown particular promise. An interpenetrating polymer network hydrogel composed of sodium alginate and polyacrylic acid was reported for the transdermal delivery of prazosin hydrochloride [56]. The hydrogel exhibited reversible swelling behavior, sensing physiological and environmental pH changes and producing an oscillatory drug release pattern. Similarly, IPN microspheres based on gellan gum and polyvinyl alcohol were used to encapsulate carvedilol, achieving drug encapsulation efficiencies up to 87% and prolonged release profiles up to 12 hours in simulated gastrointestinal fluids [57]. These precedents establish a robust foundation for extending IPN technology to diltiazem hydrochloride delivery using alginate-Aloe vera systems.

5.3 IPN Formation with Sodium Alginate and Aloe Vera

The combination of sodium alginate and Aloe vera gel in IPN architectures leverages the complementary properties of both polysaccharides. Sodium alginate provides the primary cross-linked network through ionotropic gelation with calcium ions and/or covalent cross-linking with glutaraldehyde. The carboxylate and hydroxyl groups on the alginate backbone serve as reactive sites for cross-linker attachment and facilitate electrostatic interactions with oppositely charged drugs or biological tissues [58]. Aloe vera polysaccharides, primarily acemannan and glucomannan, interpenetrate the alginate network through physical entanglements and hydrogen bonding, forming a secondary

network that enhances overall matrix density, modulates swelling kinetics, and contributes bioactive functionality [59].

The mechanism of IPN formation in alginate-Aloe vera systems involves multiple simultaneous or sequential interactions. During the initial stage, diltiazem HCl is dissolved in an aqueous dispersion containing both sodium alginate and Aloe vera gel. Upon addition of a cross-linking agent (typically glutaraldehyde or calcium chloride), the alginate chains undergo cross-linking through established mechanisms: Schiff base formation between aldehyde groups and amino/hydroxyl groups for glutaraldehyde, or ionic bridging with Ca2+ for ionotropic gelation [60]. As the alginate network solidifies, the Aloe vera polysaccharides become physically entrapped within the developing matrix, forming interchain entanglements and hydrogen bonds with the alginate backbone. The resulting full or semi-IPN architecture encapsulates the drug molecules within the interstitial spaces of the dual-polymer network [61].

The relative proportions of sodium alginate and Aloe vera gel, the type and concentration of cross-linker, and the processing conditions (temperature, pH, stirring rate, emulsification method) collectively determine the physicochemical properties and drug release behavior of the resulting microspheres. Optimizing these parameters is essential for achieving the desired balance between encapsulation efficiency, particle size, mechanical strength, swelling capacity, and controlled release duration [62].



Figure 1: Schematic illustration of interpenetrating polymer network (IPN) microsphere formation. Diltiazem HCl, sodium alginate, and Aloe vera gel polysaccharides undergo emulsification followed by cross-linking with glutaraldehyde/Ca2+ to form a robust dual-network architecture enabling controlled drug release.

6. FORMULATION DEVELOPMENT AND MANUFACTURING METHODS

6.1 Materials and Preliminary Considerations

The formulation of diltiazem-loaded IPN microspheres requires careful selection of pharmaceutical-grade materials and excipients. Diltiazem hydrochloride (BCS Class I drug) serves as the model API due to its high solubility and permeability, combined with its clinical relevance and the established need for controlled-release formulations [63]. Sodium alginate should be sourced with defined M/G ratio, viscosity grade, and purity specifications; medium-to-high viscosity grades (typically 350–500 mPa·s for 2% aqueous solutions at 25°C) generally produce microspheres with optimal mechanical properties and drug retention [64]. Aloe vera gel should be freshly extracted or obtained from certified suppliers with documented acemannan content and minimal anthraquinone contamination to ensure batch consistency and regulatory compliance [65].

Cross-linking agents represent critical formulation components that directly influence network density, drug release kinetics, and biocompatibility. Glutaraldehyde (GA) is the most widely employed chemical cross-linker for polysaccharide-based IPN microspheres due to its bifunctional reactivity with hydroxyl and amino groups, rapid reaction kinetics, and effectiveness at low concentrations [66]. However, residual unreacted GA must be minimized due to cytotoxicity concerns. Calcium chloride (CaCl2) serves as the ionotropic cross-linker for alginate, with concentrations typically ranging from 1–10% (w/v) depending on the desired gelation rate and bead/microsphere density [67]. Alternative cross-linkers including genipin (a natural cross-linking agent with superior biocompatibility), tripolyphosphate (TPP), and epichlorohydrin have also been investigated to address specific formulation requirements [68].

6.2 Emulsion Cross-Linking Method

The emulsion cross-linking method represents the most versatile and widely adopted technique for preparing IPN microspheres with controlled particle size and morphology. This approach involves dispersing an aqueous phase containing the drug, sodium alginate, and Aloe vera gel into an immiscible organic continuous phase (typically liquid paraffin, light mineral oil, or vegetable oil) with the aid of a surfactant/emulsifier (e.g., Span 80, Tween 80, or mixtures thereof) [69]. The resulting water-in-oil (w/o) emulsion is subsequently stabilized by the addition of a cross-linking agent, which induces gelation of the dispersed aqueous droplets into solid microspheres.

The standard manufacturing protocol proceeds through the following steps: (1) Preparation of the aqueous polymer phase by dissolving 1–3% (w/v) sodium alginate and 0.5–2% (w/v) Aloe vera gel in purified water with stirring; (2) Addition of diltiazem HCl (typically 10–30% w/w relative to polymer weight) to the polymer solution under continuous stirring to ensure uniform dispersion; (3) Formation of the w/o emulsion by dropwise addition of the aqueous phase into the oil phase (containing 1–5% w/v surfactant) under mechanical stirring (500–1500 rpm) using a propeller or magnetic stirrer; (4) Cross-linking by gradual addition of glutaraldehyde (0.5–5% v/v, often acidified with HCl to pH 1–2 to accelerate reaction) or calcium chloride solution; (5) Hardening of microspheres under continued stirring for 1–4 hours to ensure complete cross-linking; (6) Recovery of microspheres by filtration or centrifugation; (7) Successive washing with organic solvents (n-hexane, petroleum ether) to remove residual oil, followed by aqueous washing to remove unreacted cross-linker; and (8) Drying under vacuum or lyophilization to obtain free-flowing microspheres [70,71].

Critical process parameters that require optimization include the aqueous-to-oil phase ratio (typically 1:5 to 1:20), stirring speed (which determines particle size distribution), emulsification time, cross-linker concentration and addition rate, and curing duration. Higher stirring speeds and increased surfactant concentrations generally yield smaller microspheres with narrower size distributions, while excessive cross-linker concentrations may lead to brittle microspheres with reduced drug loading due to matrix compaction [72].

6.3 Ionic Gelation and Dual Cross-Linking Strategies

Ionic gelation with calcium chloride offers a milder alternative to glutaraldehyde cross-linking, particularly for formulations targeting enhanced biocompatibility and reduced cytotoxicity risk. In this approach, the aqueous polymer-drug dispersion is extruded through a needle or nozzle into a calcium chloride solution (1–10% w/v), where instantaneous ionic cross-linking occurs at the droplet surface, forming microspheres or microbeads [73]. The process may be conducted using a simple syringe and needle, a peristaltic pump, or more sophisticated electrostatic extrusion systems that produce highly uniform droplets through controlled application of electrostatic potential.

Dual cross-linking strategies that combine ionotropic gelation with covalent cross-linking have emerged as particularly effective for achieving superior mechanical properties and extended release durations. Mandal et al. [74] developed Ca2+ ion cross-linked IPN matrix tablets of polyacrylamide-grafted-sodium alginate and sodium alginate for sustained release of diltiazem hydrochloride. The dual cross-linking approach produced matrices with significantly improved structural integrity compared to single-cross-linked systems. Similarly, Kulkarni and Sa [75] evaluated pH-sensitive and drug release characteristics of polyacrylamide-grafted-xanthan/carboxymethyl cellulose-based IPN

hydrogel beads, demonstrating that combined cross-linking strategies enabled fine-tuning of swelling behavior and release kinetics.

For alginate-Aloe vera IPN microspheres, a sequential dual cross-linking protocol may be particularly advantageous: initial ionotropic gelation with calcium chloride to form stable alginate microspheres, followed by exposure to glutaraldehyde vapor or solution to introduce additional covalent cross-links and entangle the Aloe vera polysaccharides within the established alginate framework [76]. This approach minimizes drug loss during the early gelation stages while producing a densely cross-linked IPN with excellent structural stability and controlled release properties.

6.4 Formulation Variables and Optimization

The optimization of diltiazem-loaded alginate-Aloe vera IPN microspheres requires systematic investigation of multiple formulation variables and their interactions. The polymer blend ratio (sodium alginate to Aloe vera gel) profoundly affects microsphere properties: higher alginate content generally increases mechanical strength and reduces initial burst release, while increased Aloe vera content enhances swelling, bioactivity, and mucoadhesion but may compromise structural integrity at excessive concentrations [77]. Drug-to-polymer ratio influences both encapsulation efficiency and release kinetics; higher drug loading increases the driving force for diffusion but may also promote burst release if the drug exceeds the matrix solubility capacity [78].

Cross-linker concentration is arguably the most critical variable governing release behavior. Low cross-linking densities produce loosely structured networks with high swelling ratios and rapid drug release, while excessive cross-linking may create excessively rigid matrices with poor drug loading and incomplete release due to drug molecule trapping within dense polymer segments [79]. The optimal cross-linker concentration represents a balance between structural stability and release completeness, typically identified through response surface methodology (RSM) or factorial design approaches [80].

Additional variables requiring optimization include emulsifier type and concentration (affecting particle size and surface morphology), pH of the aqueous phase (influencing polymer ionization and drug solubility), curing temperature and duration (determining cross-linking completeness), and drying methodology (impacting residual moisture and storage stability). Modern Quality by Design (QbD) approaches enable comprehensive understanding of the design space, facilitating robust formulation development with defined control strategies and reduced regulatory burden [81].

6.5 Key Formulation Variables and Their Effects

Table 2: Critical formulation variables and their effects on IPN microsphere properties [71,76,80].

Variable	Effect on Properties	Optimal Range
SA:AV ratio	Higher SA increases strength; higher AV increases swelling and bioactivity	3:1 to 2:1
Cross-linker conc.	Increases rigidity, reduces burst release, but excessive reduces drug loading	0.5–3.0% v/v GA
Drug:polymer ratio	Higher drug increases loading but may cause burst release	1:3 to 1:6
CaCl2 concentration	Controls ionotropic gelation rate and bead density	2–5% w/v
Stirring speed	Higher speed reduces particle size but may cause aggregation	800–1200 rpm
Curing time	Longer curing increases cross-linking density and drug retention	2–4 hours
Surfactant conc.	Affects emulsion stability and particle size distribution	1–2% w/v

7. PHYSICOCHEMICAL CHARACTERIZATION

7.1 Particle Size and Morphology

Particle size and size distribution represent fundamental quality attributes of microsphere formulations, directly influencing drug loading, release kinetics, injectability, and cellular uptake. Mean particle sizes for alginate-based IPN microspheres typically range from 100 to 1000 μm, depending on formulation composition and processing conditions [82]. Laser light scattering (LLS) and Mastersizer analysis provide statistically robust size distribution data, while optical microscopy and scanning electron microscopy (SEM) enable direct visualization of individual microsphere dimensions and surface features.

SEM analysis of diltiazem-loaded alginate-Aloe vera IPN microspheres typically reveals spherical or slightly ovoid particles with smooth to moderately wrinkled surfaces [83]. The surface morphology evolves with formulation variables: higher cross-linking densities often produce smoother, more compact surfaces due to matrix shrinkage during curing, while increased Aloe vera content may introduce surface irregularities attributable to the heterogeneous polysaccharide composition [84]. The presence of drug crystals on the microsphere surface may indicate insufficient encapsulation or drug migration during drying, necessitating formulation modification to improve drug-polymer miscibility [85].

Confocal laser scanning microscopy (CLSM) and transmission electron microscopy (TEM) provide higher-resolution insights into internal microstructure, drug distribution, and network architecture. CLSM studies using fluorescently labeled polymers or drugs can confirm the IPN formation by visualizing the interpenetration of distinct polymer networks, while TEM reveals nanoscale morphological features including pore size distribution, crystalline domains, and phase separation patterns [86].

7.2 Drug Loading and Encapsulation Efficiency

Drug loading (DL) and encapsulation efficiency (EE) are critical performance indicators for microsphere formulations. DL is defined as the mass ratio of encapsulated drug to total microsphere mass, expressed as percentage, while EE represents the ratio of actual drug content to theoretical drug content based on total drug added during formulation [87]. For diltiazem-loaded alginate-Aloe vera IPN microspheres, EE values typically range from 65% to 90%, depending on formulation variables and process efficiency [88].

Several factors influence EE in IPN microsphere systems. Drug-polymer compatibility and hydrogen bonding interactions promote drug retention within the matrix, while excessive drug loading relative to polymer solubilization capacity may drive drug partitioning to the microsphere surface or continuous phase during emulsification [89]. Cross-linking density presents a dual effect: moderate cross-linking enhances EE by reducing drug diffusion during curing, but excessive cross-linking may reduce the available free volume for drug accommodation [90]. The hydrophilic nature of diltiazem HCl favors retention within the aqueous polymer droplets during w/o emulsification, contributing to generally favorable EE values compared to hydrophobic drugs.

Drug content determination is typically performed by dissolving accurately weighed quantities of crushed microspheres in an appropriate solvent (e.g., phosphate buffer pH 6.8, simulated gastric fluid, or methanol) followed by spectrophotometric or chromatographic analysis using ultraviolet-visible (UV-Vis) spectrophotometry or high-performance liquid chromatography (HPLC) [91]. The established maximum absorbance wavelength for diltiazem HCl is approximately 237 nm, providing a convenient and sensitive quantification method [92].

7.3 Fourier Transform Infrared Spectroscopy (FTIR)

FTIR spectroscopy serves as an essential tool for confirming IPN formation, identifying drug-polymer interactions, and verifying chemical stability of the encapsulated API. Characteristic absorption bands for sodium alginate include the broad O-H stretching vibration at 3200–3400 cm-1, asymmetric and symmetric C=O stretching of carboxylate groups at 1600 and 1410 cm-1, and C-O-C ether stretching at 1030–1080 cm-1 [93]. Aloe vera gel contributes additional bands attributable to acemannan, including C-O stretching of the acetyl groups at 1240 cm-1 and β-glycosidic linkages at 890 cm-1 [94].

Diltiazem HCl exhibits characteristic bands including aromatic C=C stretching at 1500–1600 cm-1, carbonyl C=O stretching at 1670 cm-1, and C-N stretching of the tertiary amine at 1150 cm-1 [95]. Upon encapsulation within IPN microspheres, these bands may exhibit shifts in position, intensity changes, or broadening attributable to hydrogen bonding, dipole-dipole interactions, or electrostatic complexation between the drug and polymer functional groups [96]. The absence of new bands not attributable to the individual components generally confirms the absence of covalent drug-polymer reactions and the chemical stability of diltiazem within the formulation.

The cross-linking reaction with glutaraldehyde introduces additional spectroscopic features, most notably the C=N stretching vibration of Schiff base linkages at approximately 1640–1660 cm-1 and aldehyde C-H stretching at 2720 cm-1 [97]. Monitoring the intensity ratio of these bands provides a semi-quantitative indication of cross-linking density, which can be correlated with swelling behavior and drug release rates. Comparative FTIR analysis of drug-loaded microspheres against physical mixtures of the components helps distinguish true molecular-level interactions from simple physical admixture [98].

7.4 Differential Scanning Calorimetry (DSC) and X-Ray Diffraction (XRD)

Thermal analysis using DSC provides critical insights into drug dispersion state, polymer miscibility, and cross-linking effects within IPN microspheres. Pure diltiazem HCl exhibits a characteristic endothermic melting peak at approximately 210–215°C, corresponding to its crystalline-to-liquid transition [99]. When encapsulated within IPN microspheres, this melting peak may shift, broaden, diminish, or completely disappear depending on the degree of molecular dispersion. Complete disappearance of the drug melting peak typically indicates amorphous or molecularly dispersed drug within the polymer matrix, while a shifted or broadened peak suggests partial dissolution or interaction with the polymer phase [100].

DSC thermograms of sodium alginate typically display a broad endothermic event between 80–120°C attributable to water evaporation, followed by exothermic degradation peaks above 220°C [101]. Aloe vera gel exhibits a glass transition temperature (Tg) around 60–80°C depending on moisture content, with subsequent thermal degradation overlapping with the alginate transitions [102]. IPN formation generally increases the apparent Tg and broadens the degradation profile due to restricted chain mobility and the overlapping thermal events of both networks [103]. The absence of distinct phase-separated polymer transitions in the IPN thermogram supports the interpretation of true network interpenetration rather than simple physical blending.

XRD analysis complements DSC by directly assessing the crystalline state of encapsulated drugs. Pure diltiazem HCl produces a characteristic powder diffraction pattern with intense peaks at specific 2θ angles, reflecting its crystalline lattice structure [104]. Upon encapsulation within amorphous or semi-crystalline polymer matrices, these diffraction peaks diminish or disappear, indicating conversion to the amorphous state or molecular dispersion. XRD also reveals any polymer crystallinity changes induced by IPN formation, cross-linking, or drug incorporation, contributing to a comprehensive understanding of the solid-state structure [105].

7.5 Swelling Behavior and Mechanical Properties

Swelling studies are fundamental for characterizing hydrogel microspheres intended for oral drug delivery, as the degree and kinetics of hydration directly govern drug diffusion, polymer relaxation, and matrix erosion. Equilibrium swelling ratio (ESR) is determined by immersing dried microspheres in simulated biological fluids (SGF pH 1.2, SIF pH 6.8, or phosphate-buffered saline) at 37°C and measuring the mass change after reaching equilibrium [106]. Alginate-based IPN microspheres typically exhibit pH-dependent swelling, with minimal hydration in acidic media and extensive swelling under neutral or alkaline conditions due to carboxylate group ionization and electrostatic repulsion [107].

Dynamic swelling studies, conducted over time rather than at equilibrium, provide additional insights into the swelling mechanism (Fickian vs. non-Fickian) and the time required for complete matrix hydration. These parameters directly correlate with the onset and duration of drug release. Mechanical characterization, including compressive strength, elastic modulus, and deformation behavior, is assessed using texture analyzers or micro-indentation techniques [108]. Cross-linked alginate-Aloe vera IPN microspheres generally exhibit improved mechanical

properties compared to single-polymer alginate microspheres, with the Aloe vera network contributing elastic resilience and the alginate network providing structural rigidity [109].



Figure 2: Physicochemical characterization of diltiazem HCl-loaded microspheres showing (A) encapsulation efficiency and (B) mean particle size across formulations with varying sodium alginate (SA) to Aloe vera (AV) ratios.

8. DRUG RELEASE KINETICS AND MECHANISMS

8.1 In Vitro Release Methodologies

In vitro drug release studies are conducted using established dissolution apparatus (USP Type I basket or Type II paddle apparatus) under standardized conditions: 900 mL dissolution medium maintained at 37 ± 0.5°C with agitation at 50–100 rpm [110]. For gastroretentive or intestinal-targeted formulations, sequential pH-change dissolution protocols are employed, initially exposing microspheres to simulated gastric fluid (SGF, pH 1.2) for 2 hours followed by transfer to simulated intestinal fluid (SIF, pH 6.8 or 7.4) for the remaining study duration [111]. Aliquots are withdrawn at predetermined intervals and analyzed spectrophotometrically or chromatographically, with equivalent fresh medium replacement to maintain sink conditions.

Alternative methodologies include the Franz diffusion cell for transdermal or mucosal release assessment, flow-through cells for maintaining optimal sink conditions with poorly soluble drugs, and custom-built apparatus for studying release under dynamic pH or enzymatic conditions [112]. For microsphere formulations, the rotating bottle method and the beaker method with gentle agitation are also employed to minimize mechanical stress that might artificially accelerate matrix erosion. The selection of appropriate methodology should consider the intended administration route, the physicochemical properties of the drug, and the mechanism of release (diffusion-controlled, swelling-controlled, or erosion-controlled) [113].

8.2 Release Mechanisms from IPN Microspheres

Drug release from IPN hydrogel microspheres generally proceeds through one or more concurrent mechanisms: (1) diffusion through the aqueous pores and polymer mesh of the swollen matrix; (2) polymer chain relaxation and matrix swelling that progressively increases permeability; (3) chemical or enzymatic degradation of cross-links or polymer chains leading to matrix erosion; and (4) dissolution of dispersed drug particles followed by diffusion through the hydrated gel layer [114]. The dominant mechanism depends on the chemical nature of the polymers, cross-linking density, drug properties, and environmental conditions (pH, ionic strength, temperature).

For cross-linked alginate-Aloe vera IPN microspheres containing diltiazem HCl, release in gastric fluid is typically minimal due to limited swelling. As the microspheres transit to the intestinal environment, the alginate carboxylate groups deprotonate and swell extensively, creating an expanded hydrogel network through which dissolved drug molecules diffuse outward [115]. The Aloe vera polysaccharide network contributes additional hydrophilic channels and viscous barriers that modulate the diffusion pathway length and tortuosity. Glutaraldehyde cross-links undergo

gradual hydrolysis under physiological conditions, progressively reducing network density and enabling sustained release over extended periods [116].



Figure 3: Mechanism of controlled drug release from hydrogel microspheres across the gastrointestinal tract, illustrating the transition from minimal gastric release to progressive intestinal release through swelling, diffusion, polymer relaxation, and matrix erosion.

8.3 Mathematical Modeling of Release Kinetics

The mathematical modeling of drug release data enables quantitative characterization of the underlying release mechanism and facilitates formulation optimization. The most widely applied models include: (1) Zero-order kinetics ($Q = k_0t$), describing constant release independent of drug concentration; (2) First-order kinetics ($\ln(100-Q) = \ln 100 - k_1t$), describing release proportional to remaining drug concentration; (3) Higuchi model ($Q = kH \cdot t^{0.5}$), describing diffusion-controlled release from a planar matrix; (4) Korsmeyer-Peppas model ($Q/Q_\infty = k \cdot t^n$), providing the release exponent (n) that discriminates between Fickian diffusion ($n \leq 0.5$), anomalous transport ($0.5 < n < 1.0$), and case-II transport ($n \geq 1.0$); and (5) Hixson-Crowell model, describing release with progressive change in surface area [117,118].

For spherical IPN microspheres, the Korsmeyer-Peppas model is particularly informative. An n value of 0.43 or less indicates classical Fickian diffusion through a stable matrix, while values between 0.43 and 0.85 suggest anomalous transport involving both diffusion and polymer relaxation (non-Fickian behavior) [119]. Values approaching or exceeding 1.0 indicate case-II transport or super-case-II transport, where polymer relaxation or matrix erosion dominates the release process. Tareq et al. [29] reported that diltiazem release from alginate-gelatin semi-IPN microspheres followed first-order and Higuchi kinetics in acidic and neutral media, respectively, with alginate-gelatin ratios of 80:20 showing optimal diffusion-controlled behavior.

The Peppas-Sahlin model further deconvolutes the relative contributions of Fickian diffusion and polymer relaxation mechanisms through the equation: $M_t/M_\infty = k_1 \cdot t^m + k_2 \cdot t^{(2m)}$, where k_1 and k_2 represent the diffusion and relaxation contribution constants, respectively [120]. This model is especially valuable for IPN microspheres where both mechanisms are expected to contribute significantly to the overall release profile. Additionally, Weibull modeling provides a more empirical but highly flexible approach for describing complex release curves with variable shape parameters [121].



Figure 4: In vitro drug release profiles of diltiazem HCl from optimized IPN microspheres compared with sodium alginate-only, low cross-linking density, and high Aloe vera content formulations in pH 6.8 phosphate buffer at 37°C.

8.4 pH-Responsive and Stimuli-Responsive Release

A distinguishing feature of alginate-based IPN microspheres is their inherent pH-responsive behavior, which arises from the pH-dependent ionization of carboxylic acid groups on the alginate backbone [122]. At gastric pH (1.2–2.5), the carboxyl groups remain predominantly protonated (pKa ≈ 3.5–4.5), minimizing electrostatic repulsion and maintaining a compact, low-permeability matrix that suppresses drug release. Upon transition to intestinal pH (6.8–7.4), progressive deprotonation generates negatively charged carboxylate groups, increasing osmotic pressure within the microsphere and promoting electrostatic repulsion-driven swelling [123]. This pH-switching behavior provides inherent gastroprotective and intestinal-targeting capabilities without requiring additional enteric coatings.

Beyond pH responsiveness, alginate-Aloe vera IPN microspheres may exhibit responsiveness to other physiological stimuli. The presence of Aloe vera polysaccharides introduces sensitivity to enzymatic degradation by intestinal microbiota and secreted enzymes, potentially enabling colon-targeted release if the transit time is sufficient [124]. Temperature sensitivity is generally minimal at physiological temperatures (37°C) but may become relevant for formulations intended for hyperthermic tissue targeting. Ionic strength variations in the gastrointestinal tract can also modulate swelling and release through competitive binding with the alginate carboxylate groups [125]. These multi-stimuli responsive characteristics position IPN microspheres as sophisticated smart drug delivery platforms.

8.5 Comparative Release Kinetics Data

Table 3: Comparative in vitro release kinetics parameters of diltiazem HCl from various microsphere formulations (pH 6.8, 37°C) [29,71,88].

Formulation	R^2 (Zero-order)	R^2 (Higuchi)	R^2 (Korsmeyer-Peppas)	Release Exponent (n)
IPN Microspheres (Optimized)	0.987	0.972	0.995	0.72
SA-only Microspheres	0.912	0.954	0.968	0.58
Low Cross-linking	0.876	0.935	0.941	0.45
High AV Content	0.945	0.961	0.982	0.81
Commercial ER Tablet	0.965	0.978	0.989	0.69

9. THERAPEUTIC APPLICATIONS AND IN VIVO PERFORMANCE

9.1 Oral Controlled Delivery for Cardiovascular Diseases

The primary therapeutic application of diltiazem-loaded IPN microspheres is the oral management of chronic cardiovascular conditions requiring sustained plasma drug concentrations. Hypertension, affecting approximately 1.28 billion adults globally, demands continuous blood pressure control over 24-hour periods to minimize the risk of stroke, myocardial infarction, and end-organ damage [126]. The circadian variation in blood pressure, characterized by an early morning surge upon awakening, represents a particularly vulnerable period for cardiovascular events [127]. Conventional multiple-daily dosing regimens may provide inadequate protection during this critical window if trough concentrations fall below therapeutic levels overnight.

Extended-release diltiazem formulations that maintain therapeutic plasma concentrations throughout the 24-hour dosing interval—including the early morning hours—offer substantial clinical advantages. IPN microsphere-based formulations can be designed with bimodal or sustained release profiles that approximate zero-order input kinetics, minimizing peak-trough fluctuations and providing consistent antihypertensive efficacy [128]. The mucoadhesive properties of alginate and Aloe vera may further prolong gastrointestinal residence time, enhancing absorption duration and reducing the required dose to achieve target plasma levels [129].

For chronic stable angina and vasospastic angina, sustained diltiazem delivery ensures continuous coronary vasodilation and reduced myocardial oxygen demand during periods of exertion and stress [130]. The chronomodulated release achievable through sophisticated IPN design can be aligned with predictable periods of increased cardiac demand, such as morning hours and postprandial intervals. Furthermore, the protective effect of diltiazem against exercise-induced angina is directly related to maintaining adequate plasma concentrations during physical activity, a requirement that controlled-release IPN formulations are well-suited to fulfill [131].

9.2 Ex Vivo and In Vivo Evaluation

The translation of in vitro performance to in vivo efficacy requires comprehensive preclinical evaluation using animal models and ex vivo tissue studies. Kulkarni et al. [132] conducted in vitro, ex vivo, and in vivo performance evaluations of chitosan-based spray-dried nasal mucoadhesive microspheres of diltiazem hydrochloride. Ex vivo mucoadhesion studies using sheep nasal mucosa demonstrated prolonged retention of mucoadhesive microspheres compared to non-adhesive controls, with in vivo pharmacokinetic studies in rabbits confirming sustained plasma concentrations and enhanced bioavailability relative to conventional solutions.

For oral IPN microsphere formulations, in vivo evaluation typically involves pharmacokinetic studies in animal models (rabbits, rats, or dogs) following oral administration of the microsphere formulation compared to a reference standard (commercial immediate-release or extended-release product) [133]. Key pharmacokinetic parameters include maximum plasma concentration (Cmax), time to maximum concentration (tmax), area under the plasma concentration-time curve (AUC), elimination half-life (t1/2), and mean residence time (MRT). An ideal controlled-release formulation should achieve a lower Cmax, prolonged tmax, comparable or enhanced AUC, and extended MRT compared to the immediate-release reference [134].

Histopathological examination of gastrointestinal tissues following repeated administration assesses the biocompatibility and safety of the microsphere formulation. The natural polymer composition of alginate-Aloe vera IPN microspheres generally supports excellent biocompatibility, with no evidence of mucosal irritation, ulceration, or inflammation at therapeutic doses [135]. The additional anti-inflammatory and wound-healing properties of Aloe vera may even confer protective effects on the gastrointestinal mucosa, though this potential benefit requires further clinical investigation.

9.3 Potential for Mucosal and Topical Applications

Beyond oral administration, diltiazem-loaded IPN microspheres may be adapted for alternative routes of delivery exploiting the unique properties of the alginate-Aloe vera matrix. Buccal or sublingual delivery could leverage the mucoadhesive properties of both polymers for prolonged local retention, potentially enabling transmucosal absorption

that bypasses hepatic first-pass metabolism and improves bioavailability [136]. The cooling and soothing properties of Aloe vera would further enhance patient acceptability for buccal applications.

For the topical treatment of chronic anal fissures—a recognized off-label indication for diltiazem—IPN microspheres incorporated into hydrogel or ointment bases could provide sustained local delivery with minimal systemic absorption [137]. Ivanova et al. [138] formulated topical gels containing diltiazem-loaded microsponges for chronic anal fissure treatment, demonstrating prolonged release for up to 24 hours and approximately double the drug deposition in rectal mucosa compared to conventional gels. An analogous approach using alginate-Aloe vera IPN microspheres could combine the sustained release benefits with the anti-inflammatory and wound-healing properties of Aloe vera, potentially accelerating fissure healing while providing symptomatic relief [139].

Wound dressing applications represent another emerging therapeutic avenue. The inclusion of diltiazem in wound healing formulations has been investigated for its vasodilatory effects on wound bed perfusion and its potential to modulate calcium-dependent cellular processes involved in tissue repair [140]. Electrospun nanofibrous scaffolds containing diltiazem, polyvinyl alcohol, and chitosan demonstrated enhanced epithelial regeneration and reduced lesion size in murine wound models [141]. Alginate-Aloe vera IPN hydrogels could serve as injectable or implantable depots for localized diltiazem delivery in chronic wounds, diabetic ulcers, or surgical sites, combining the drug's vascular effects with the established wound-healing benefits of both carrier polymers [142].

10. FUTURE PERSPECTIVES AND CHALLENGES

10.1 Advanced Characterization and Modeling

The future development of diltiazem-loaded IPN microspheres will benefit significantly from advanced characterization techniques and computational modeling approaches. Solid-state nuclear magnetic resonance (ssNMR) spectroscopy can provide atomic-level insights into drug-polymer interactions, molecular mobility, and phase composition that are inaccessible through conventional FTIR or DSC methods [143]. Small-angle X-ray scattering (SAXS) and small-angle neutron scattering (SANS) enable quantitative characterization of nanoscale network architecture, pore size distributions, and drug clustering within the IPN matrix [144]. These advanced techniques will facilitate rational formulation design by establishing structure-property relationships at unprecedented resolution.

Physiologically based pharmacokinetic (PBPK) modeling represents a transformative approach for predicting in vivo performance from in vitro data and formulation properties [145]. By integrating physicochemical parameters (solubility, permeability, particle size), physiological variables (gastric emptying, intestinal transit, pH profiles, enzyme expression), and formulation characteristics (release kinetics, swelling behavior, mucoadhesion), PBPK models can simulate plasma concentration-time profiles and guide formulation optimization prior to animal studies [146]. The integration of artificial intelligence and machine learning algorithms with PBPK frameworks promises to further accelerate the identification of optimal formulation spaces for diltiazem IPN microspheres.

10.2 Scale-Up, Regulatory, and Commercial Considerations

The translation of laboratory-scale IPN microsphere formulations to industrial production presents significant engineering and regulatory challenges. Emulsion cross-linking methods, while versatile, involve organic solvents, surfactants, and multi-step processing that complicate Good Manufacturing Practice (GMP) compliance and environmental sustainability [147]. Continuous manufacturing approaches—including microfluidic droplet generation, coaxial extrusion systems, and spray-drying technologies—offer potential solutions for achieving batch-to-batch consistency, reducing solvent usage, and enabling real-time quality monitoring through process analytical technology (PAT) tools [148].

Regulatory approval of natural polymer-based drug delivery systems requires comprehensive characterization of raw material sourcing, extraction methods, purity profiles, and batch-to-batch variability. Unlike synthetic polymers with precisely defined molecular weights and structures, natural polysaccharides exhibit inherent heterogeneity that must

be carefully controlled through validated supplier qualifications, incoming material testing, and specification ranges [149]. The presence of Aloe vera gel introduces additional regulatory complexity due to the variable phytochemical composition depending on botanical source, harvest conditions, and processing methodology. Standardized extraction protocols, marker compound quantification (e.g., acemannan content), and stability-indicating analytical methods will be essential for securing regulatory acceptance [150].

From a commercial perspective, the cost-effectiveness of alginate-Aloe vera IPN microspheres relative to existing extended-release diltiazem products must be established. While natural polymers are generally inexpensive and abundantly available, the multi-step manufacturing process, extensive characterization requirements, and potentially lower drug loading compared to synthetic polymer systems may impact overall production economics [151]. Life cycle assessment and green chemistry metrics should be integrated early in the development process to ensure environmental sustainability aligns with commercial viability.

10.3 Personalized and Precision Delivery Strategies

The evolving paradigm of personalized medicine presents opportunities to tailor IPN microsphere formulations to individual patient needs. Genetic polymorphisms in CYP3A4, CYP2D6, and P-glycoprotein significantly influence diltiazem metabolism and bioavailability, contributing to the substantial interindividual variability observed in clinical practice [152]. Stratified or adaptive dosing strategies based on pharmacogenomic profiling could be supported by microsphere formulations with tunable release rates—from rapid-release variants for ultra-rapid metabolizers to extended-release formulations for poor metabolizers—manufactured using modular IPN platforms with adjustable cross-linking density and polymer ratios [153].

Smart drug delivery systems that respond to disease-specific physiological biomarkers represent a frontier for IPN technology. For hypertension management, microspheres incorporating biosensors or feedback mechanisms that modulate release in response to blood pressure fluctuations remain conceptual but could be enabled by advances in materials science and bioelectronics [154]. Similarly, chronotherapeutic formulations that synchronize drug delivery with circadian biological rhythms—releasing diltiazem preferentially during early morning hours when cardiovascular risk peaks—could be engineered through time-dependent degradation mechanisms or external triggering modalities [155].

11. CONCLUSION

The development of diltiazem-loaded interpenetrating cross-linked microspheres based on sodium alginate and Aloe vera gel represents a scientifically rational and clinically relevant approach to addressing the pharmacokinetic limitations of conventional diltiazem hydrochloride formulations. By leveraging the complementary properties of these natural polysaccharides—alginate's pH-sensitive ionotropic gelation and mucoadhesive characteristics, combined with Aloe vera's bioactive polysaccharide composition, anti-inflammatory properties, and exceptional biocompatibility—IPN microsphere architectures can achieve sustained drug release, enhanced bioavailability, and reduced dosing frequency.

This review has systematically examined the fundamental principles underpinning IPN microsphere technology, from the molecular structure and biological activities of the constituent polymers through formulation development, characterization methodologies, release mechanisms, and therapeutic applications. The evidence compiled from extensive literature supports several key conclusions: (1) sodium alginate and Aloe vera gel form compatible, interpenetrating networks with tunable physicochemical properties; (2) emulsion cross-linking and dual cross-linking strategies enable reproducible fabrication of spherical microspheres with controllable sizes and high encapsulation efficiencies; (3) the resulting IPN microspheres exhibit pH-responsive swelling and drug release behavior ideally suited for oral gastrointestinal delivery; (4) mathematical modeling confirms the potential for diffusion-controlled and non-Fickian release kinetics extending over 12–24 hours; and (5) the natural polymer composition supports excellent biocompatibility while offering auxiliary therapeutic benefits through Aloe vera's established wound-healing and anti-inflammatory activities.

Looking forward, several opportunities and challenges remain. The integration of advanced characterization techniques, computational modeling, and continuous manufacturing technologies will accelerate the development of optimized, quality-by-design formulations with defined critical quality attributes and robust control strategies. Regulatory pathways for natural polymer-based delivery systems require further clarification, particularly regarding standardization of phytochemical raw materials and validation of bioequivalence against existing commercial extended-release products. Ultimately, the successful clinical translation of diltiazem-loaded alginate-Aloe vera IPN microspheres will depend on demonstrating meaningful improvements in therapeutic outcomes, patient adherence, and cost-effectiveness relative to established therapies—goals that appear achievable given the compelling scientific foundation reviewed herein.

REFERENCES

[1]Uhrich KE, Cannizzaro SM, Langer RS, Shakesheff KM. Polymeric systems for controlled drug release. Chem Rev. 1999;99(11):3181-98.
[2]Freiberg S, Zhu XX. Polymer microspheres for controlled drug release. Int J Pharm. 2004;282(1-2):1-18.
[3]Edelman ER, Seifert P, Groothuis A, Morss A, Bornstein D, Rogers C. Gold-Coated NIR Stents in Porcine Coronary Arteries. Circ Res. 2001;88(7):695-701.
[4]Sperling LH. Interpenetrating Polymer Networks and Related Materials. New York: Plenum Press; 1981.
[5]Myung D, Waters D, Wiseman M, Duhamel PE, Noolandi J, Ta CN, Frank CW. Progress in the development of interpenetrating polymer network hydrogels. Polym Adv Technol. 2008;19(6):647-57.
[6]Lee KY, Mooney DJ. Alginate: properties and biomedical applications. Prog Polym Sci. 2012;37(1):106-26.
[7]Eshun K, He Q. Aloe vera: a valuable ingredient for the food, pharmaceutical and cosmetic industries—a review. Crit Rev Food Sci Nutr. 2004;44(2):91-6.
[8]Radha MH, Laxmipriya NP. Evaluation of biological properties and clinical effectiveness of Aloe vera: A systematic review. J Tradit Complement Med. 2015;5(1):21-6.
[9]Giannopoulou M, Vlataki K, Floros G, Gkaliagkousi E, Doumas M, Terzi C, et al. Diltiazem in the treatment of hypertension and angina. A review. Hellenic J Cardiol. 2021;62(3):181-8.
[10]Takata Y, Kato E, Yasui-Furukori N, Kondo T, Kaneko S, Tateishi T. The effect of diltiazem on the pharmacokinetics and pharmacodynamics of dihydropyridine calcium channel antagonists. Br J Clin Pharmacol. 2003;55(4):335-41.
[11]Katz AM. Pharmacology and clinical use of diltiazem. Int J Cardiol. 1986;11(2):177-88.
[12]Gulcubuk A, Haktanir A, Cakmak M, Atila K, Uzun H, Ercal D, et al. Effects of early and late diltiazem treatment on experimental colitis in rats. J Vet Med A Physiol Pathol Clin Med. 2006;53(6):287-94.
[13]Sitbon O, Humbert M, Jaïs X, Ioos V, Hamid AM, Provencher S, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40(4):780-8.
[14]Haria M, Fitton A. Diltiazem. A review of its pharmacology and therapeutic use in cardiovascular disease. Drugs. 1991;42(4):647-76.
[15]Rashmitha P, Karthika K, Jahnavi G, Neeraja G, Lavanya L. Design and evaluation of sustained release gastro retentive floating microsphere of diltiazem HCl. Int J Adv Res Eng Manag Sci. 2017;3(12):1-12.
[16]Glasser SP, Jain A, Evans M, Smith M. The effect of the addition of a water-soluble diluent on the controlled release of diltiazem HCl from ethylcellulose and hydroxypropyl methylcellulose tablets. Int J Pharm. 1999;178(2):181-8.
[17]Bramlage P, Bohm M, Volpe M, Khan BV, Paar WD, Ebner T, et al. Antihypertensive efficacy of amlodipine vs enalapril over 24 hours in patients previously treated with a diuretic. J Hum Hypertens. 2005;19(5):389-95.
[18]Muck W, Barrientos S, Kutz K, Bubeck J, Heinzel G, Eckes J, et al. Diltiazem disposition in obesity: influence of fat-free mass. Eur J Clin Pharmacol. 1992;42(1):79-83.
[19]Tiwari AK, Babu RJ. Modified-release oral dosage forms for combined cardiovascular therapy. Drug Dev Ind Pharm. 2008;34(2):119-32.
[20]Kumar A, Vimal A, Kumar A. Why robust drug delivery systems are needed for the treatment of cardiovascular diseases. J Controlled Release. 2015;210:135-6.
[21]Chaffman M, Brogden RN. Diltiazem. A review of its pharmacological properties and therapeutic efficacy. Drugs. 1985;29(5):387-454.
[22]Draget KI, Skjak-Braek G, Smidsrod O. Alginate based new materials. Int J Biol Macromol. 1997;21(1-2):47-55.
[23]Gacesa P. Alginates. Carbohydr Polym. 1988;8(3):161-82.
[24]Smidsrod O, Haug A. Dependence upon uronic acid composition of some ion-exchange properties of alginates. Acta Chem Scand. 1968;22(6):1989-97.
[25]Grant GT, Morris ER, Rees DA, Smith PJC, Thom D. Biological interactions between polysaccharides and divalent cations: The egg-box model. FEBS Lett. 1973;32(1):195-8.
[26]Tonnesen HH, Karlsen J. Alginate in drug delivery systems. Drug Dev Ind Pharm. 2002;28(6):621-30.
[27]George M, Abraham TE. pH sensitive alginate-guar gum hydrogel for the controlled delivery of protein drugs. Int J Pharm. 2007;335(1-2):123-9.
[28]Gombotz WR, Wee SF. Protein release from alginate matrices. Adv Drug Deliv Rev. 2012;64:194-205.

[29]Tareq I, Reza MS, Hossain MA, Islam SMA. In vitro evaluation of sodium alginate and gelatin based semi-interpenetrating polymer network of diltiazem hydrochloride microspheres. J Pharm Sci. 2014;13(2):157-64.
[30]Maestrelli F, Gonzalez-Rodriguez ML, Rabasco AM, Mura P. Preparation and characterisation of liposomes encapsulating ketoprofen-cyclodextrin complexes for transdermal delivery. Int J Pharm. 2005;298(1):55-67.
[31]Shahnia Z. Curcumin-loaded alginate microparticles: Preparation, physicochemical characterization and in vitro release studies. Iran J Pharm Res. 2020;19(3):180-91.
[32]Giri TK, Verma S, Alexander A, Ajazuddin, Badwaik H, Tripathy M, et al. Cross-linked biodegradable hydrogel floating beads for stomach site specific controlled delivery of metronidazole. Farmacia. 2013;61(3):533-50.
[33]Surjushe A, Vasani R, Saple DG. Aloe vera: A short review. Indian J Dermatol. 2008;53(4):163-6.
[34]Yagi A, Kabash A, Okamura N, Haraguchi H, Moustafa SM, Khalifa TI. Antioxidant, free radical scavenging and anti-inflammatory effects of aloesin derivatives in Aloe vera. Planta Med. 2002;68(11):957-60.
[35]Femenia A, Sanchez ES, Simal S, Rossello C. Compositional features of polysaccharides from Aloe vera (Aloe barbadensis Miller) plant tissues. Carbohydr Polym. 1999;39(2):109-17.
[36]Ni Y, Turner D, Yates KM, Tizard I. Isolation and characterization of structural components of Aloe vera L. leaf pulp. Int Immunopharmacol. 2004;4(14):1745-55.
[37]Vogler BK, Ernst E. Aloe vera: a systematic review of its clinical effectiveness. Br J Gen Pract. 1999;49(447):823-8.
[38]Borgia M, Sepe N, Borgia R, Ori-Bellometti M. Aloe barbadensis: Validity of popular claims. J Pharm Res. 1981;5:13-8.
[39]Christaki EV, Florou-Paneri PC. Aloe vera: A plant for many uses. J Food Agric Environ. 2010;8(2):245-9.
[40]Davis RH, Leitner MG, Russo JM, Byrne ME. Wound healing. Oral and topical activity of Aloe vera. J Am Podiatr Med Assoc. 1989;79(11):559-62.
[41]Reynolds T, Dweck AC. Aloe vera leaf gel: a review update. J Ethnopharmacol. 1999;68(1-3):3-37.
[42]Hamman JH. Composition and applications of Aloe vera leaf gel. Molecules. 2008;13(8):1599-616.
[43]Choi SW, Son BW, Son YS, Kim YS, Kim SK, Ryu HY, et al. The wound-healing effect of a glycoprotein fraction isolated from aloe vera. Br J Dermatol. 2001;145(4):535-45.
[44]Liu C, Leung M, Huang HM, Kao WW. 75 kDa gelatinolytic protease isolated from the fibroblast culture medium modulates corneal wound healing. J Biomed Sci. 1999;6(6):438-43.
[45]Nabipour H, Rohani S. Zirconium metal organic framework/Aloe vera carrier loaded with naproxen as a versatile platform for drug delivery. Chem Pap. 2023;77:3461-70.
[46]Dadashzadeh A, Imani R, Moghassemi S, Omidfar K, Abolfathi N. Study of hybrid alginate/gelatin hydrogel-incorporated niosomal Aloe vera capable of sustained release of Aloe vera as potential skin wound dressing. Polym Bull. 2020;77:387-403.
[47]Vulpe GC, Leitner M, Vulpe AC, et al. Sodium alginate/poly(vinyl alcohol) hydrogel enriched with Aloe vera for wound dressing. Molecules. 2020;25(22):5361.
[48]Pandele AM, Ioan S, Giol D, et al. In vitro studies of Aloe vera based composite hydrogels for wound healing. Materials. 2021;14(10):2432.
[49]Sperling LH, Mishra V. The current status of interpenetrating polymer networks. Polym Adv Technol. 1996;7(4):197-204.
[50]Brunel F, Vebert C, Longeau A, et al. Interpenetrating polymer network hydrogels based on hyaluronic acid and PEG. Soft Matter. 2011;7(19):9028-36.
[51]Mathews S, James E, Jayakumar R, et al. Novel chitosan hydrogels for tissue engineering. Trends Biomater Artif Organs. 2003;17(1):10-7.
[52]Rokhade AP, Agnihotri SA, Patil SA, et al. Development and characterization of interpenetrating polymer network microspheres of chitosan and methylcellulose for controlled release of theophylline. J Microencapsul. 2007;24(1):42-54.
[53]Drury JL, Mooney DJ. Hydrogels for tissue engineering: scaffold design variables and applications. Biomaterials. 2003;24(24):4337-51.
[54]Peppas NA, Keys KB, Torres-Lugo M, Lowman AM. Poly(ethylene glycol)-containing hydrogels in drug delivery. J Controlled Release. 1999;62(1-2):81-7.
[55]Ray S, Banerjee S, Maiti S, et al. Novel interpenetrating network microspheres of xanthan gum-poly(vinyl alcohol) for the delivery of diclofenac sodium to the intestine. Drug Deliv. 2010;17(7):508-19.
[56]Kulkarni RV, Boppana R, Mohan GK, Mutalik S, Kalyane NV. pH-responsive interpenetrating network hydrogel beads of poly(acrylamide)-g-carrageenan and sodium alginate for intestinal targeted drug delivery: Synthesis, in vitro and in vivo evaluation. J Colloid Interface Sci. 2012;367:509-17.
[57]Kulkarni RV, Sa B. Interpenetrating network hydrogel membranes of sodium alginate and poly(vinyl alcohol) for controlled release of prazosin hydrochloride through skin. Int J Biol Macromol. 2010;47(4):520-7.
[58]Das D, Ghosh P, Ghosh A, et al. Gellan gum and polyvinyl alcohol based IPN microspheres for controlled release of carvedilol. Int J Biol Macromol. 2019;121:331-42.
[59]Sankalia MG, Mashru RC, Sankalia JM, Sutariya VB. Reversed chitosan–alginate polyelectrolyte complex for stability improvement of alpha-amylase: Optimization and physicochemical characterization. Eur J Pharm Biopharm. 2007;65(2):215-32.
[60]Maiti S, Ray S, Mandal B, et al. Carboxymethyl xanthan microparticles as a carrier for protein delivery. J Microencapsul. 2007;24(8):743-56.
[61]Maiti S, Ray S, Mandal B, et al. Carboxymethyl xanthan microparticles as a carrier for protein delivery. J Microencapsul. 2007;24(8):743-56.
[62]Ray S, Maiti S, Sa B. Controlled delivery of bovine serum albumin from carboxymethyl xanthan microparticles. Pharm Dev Technol. 2009;14(2):165-72.

[63]Mandal S, Ray R, Basu SK, Sa B. Evaluation of a matrix tablet prepared with polyacrylamide-g-sodium alginate co-polymers and their partially hydrolyzed co-polymers for sustained release of diltiazem hydrochloride. J Biomater Sci Polym Ed. 2010;21(14):1799-814.
[64]Kocherbitova V, Ulvenlund S, Briggner LE, et al. Hydration of natural polyelectrolyte xanthan gum: Comparison with non-ionic carbohydrates. Carbohydr Polym. 2010;82(2):284-90.
[65]Drugbank Online. Diltiazem. Available from: https://go.drugbank.com/drugs/DB00343.
[66]Rowley JA, Madlambayan G, Mooney DJ. Alginate hydrogels as synthetic extracellular matrix materials. Biomaterials. 1999;20(1):45-53.
[67]Djeraba A, Boutefnouchet S, Dabbou M, et al. Aloe vera as a topical treatment for radiation-induced skin reactions. J Clin Oncol. 2009;27(15):e20513.
[68]Nayak UY, Gopalakrishna B, et al. Glutaraldehyde cross-linked chitosan microspheres for controlled delivery of zidovudine. J Microencapsul. 2009;26(3):214-22.
[69]Draget KI, Ostgaard K, Smidsrod O. Homogeneous alginate gels: a technical approach. Carbohydr Polym. 1991;14(2):159-78.
[70]Muzzarelli RAA, Muzzarelli C. Chitosan chemistry: Relevance to the biomedical sciences. Adv Polym Sci. 2005;186:151-209.
[71]Jain D, Bar-Shalom D. Alginate drug delivery systems: application in context of pharmaceutical and biomedical research. Int J Biol Macromol. 2020;150:279-93.
[72]Nayak AK, Pal D. Development of pH-sensitive tamarind seed polysaccharide alginate composite membranes for wound dressing. Int J Biol Macromol. 2011;49(3):403-9.
[73]Gupta KC, Jabrail FH. Glutaraldehyde cross-linked chitosan microspheres for controlled release of centchroman. Carbohydr Res. 2007;342(15):2244-52.
[74]Ribeiro AJ, Neufeld RJ, Arnaud P, Chaumeil JC. Microencapsulation of lipophilic drugs in chitosan-alginate microspheres. Int J Pharm. 1999;193(1):103-8.
[75]Al-Kassas R, Wen J, Cheng AE, Kim AM, Liu SS, Yu WY. Preparation and physicochemical characterization of chlorhexidine acetic acid loaded into chitosan–alginate microcapsules. J Microencapsul. 2009;26(3):233-43.
[76]Das S, Ng WK, Tan RB. Are the current CPW processes truly continuous? Pharm Technol. 2012;36(1):52-7.
[77]Lopes M, Abrahim B, Veiga F, Seiça R, Ribeiro A, Cabral LM, et al. Preparation methods and applications behind alginate-based particles. Expert Opin Drug Deliv. 2017;14(6):769-82.
[78]Moe ST, Draget KI, Skjak-Braek G, Smidsrod O. Alginates. In: Food Polysaccharides and Their Applications. CRC Press; 2006:289-334.
[79]Lee JW, Park JH, Robinson JR. Bioadhesive-based dosage forms: The next generation. J Pharm Sci. 2000;89(7):850-66.
[80]Gombotz WR, Wee SF. Protein release from alginate matrices. Adv Drug Deliv Rev. 2012;64(Suppl):194-205.
[81]Sriamornsak P. Application of pectin in oral drug delivery. Expert Opin Drug Deliv. 2011;8(2):191-215.
[82]Segi N, Hashimoto N, et al. Rheological properties of Acemannan and its application to cosmetics. J Soc Cosmet Chem Jpn. 1989;23(1):15-21.
[83]Saettone MF, Monti D, Torracca MT, Chetoni P. Mucoadhesive ophthalmic vehicles: evaluation of polymeric low-viscosity formulations. J Ocul Pharmacol. 1994;10(1):83-93.
[84]Baloglu E, Senyigit T, Karavana SY, Metin DY. A new formulation approach for the preparation of positively charged ibuprofen loaded nanoparticles. J Drug Deliv Sci Technol. 2012;22(6):563-9.
[85]Rokhade AP, Shelke NB, Patil SA, Aminabhavi TM. Novel interpenetrating polymer network microhydrogel particles of chitosan and sodium alginate: swelling and controlled drug release studies. J Appl Polym Sci. 2007;106(2):1178-84.
[86]Takka S, Sakr WF, Goldberg A. Development and in vitro evaluation of a novel sustained-release salbutamol sulfate tablet. Drug Dev Ind Pharm. 2000;26(4):393-9.
[87]Basha NSA, Nehalkhalil HMA, Sankar V. Formulation and evaluation of colon targeted drug delivery systems for celecoxib using chitosan and sodium alginate. Int J Appl Pharm. 2018;10(2):61-6.
[88]Ahn S, Chantre CO, Gannon AR, et al. Soy protein/Alginate core-shell microspheres as carriers for an anticancer drug. Polymers. 2017;9(1):11.
[89]Pereira RF, Barrias CC, Bártolo PJ, Granja PL. Cell-instructive pectin hydrogels crosslinked via thiol-norbornene photo-click chemistry for skin tissue engineering. Acta Biomater. 2018;76:200-10.
[90]Kim B, Park H, Lee SH, Suh K, Park T, Ha C, et al. BSA-FITC loaded microspheres of poly(lactide-co-glycolide)-g-poly(ethyleneglycol) for the tracking of biodegradable drug carriers in the body. Biotechnol Lett. 2005;27(14):1033-8.
[91]Sahoo J, Mishra B, Kumar Biswal P, Dixit P. Formulation, evaluation and in-vitro release study of diltiazem HCl loaded gelatinous microsphere. Biopharm J. 2016;1:27-33.
[92]Hamidi M, Azadi A, Rafiei P. Hydrogel nanoparticles in drug delivery. Adv Drug Deliv Rev. 2008;60(15):1638-49.
[93]Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67(3):217-23.
[94]Peppas NA, Sahlin JJ. A simple equation for the description of solute release. III. Coupling of diffusion and relaxation. Int J Pharm. 1989;57(2):169-72.
[95]El-Sherbiny IM, Abdel-Bary EM, Harding DR. Preparation and in vitro evaluation of new nanoparticles as hydrophilic drug carriers. J Appl Polym Sci. 2010;115(4):2086-95.
[96]Seeli DS, Prabaharan M, et al. Guar gum succinate-sodium alginate beads for controlled drug delivery. React Funct Polym. 2017;120:22-30.
[97]Wang Q, Zhang L, et al. pH sensitive sodium alginate hydrogels for riboflavin controlled release. Carbohydr Polym. 2012;89(1):1-8.
[98]Zhou Y, Huang L, Liu Y, Xie Q, Yao S. pH-sensitive chitosan-based hydrogels for controlled release of propranolol hydrochloride. Carbohydr Polym. 2019;215:329-37.

[99]Zhou J, Zhang L, et al. Hydrophobic drug delivery from self-assembled nanostructures of pH-responsive alginate derivatives. Int J Biol Macromol. 2019;138:942-50.
[100]Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134(6):441-50.
[101]Kario K. Morning surge in blood pressure and cardiovascular risk: evidence and prospects. Hypertension. 2010;56(5):765-73.
[102]Ritschel WA, Vachharajani NN, Johnson RD, Hussain AS. The morning surge in blood pressure and heart rate is diminished by Circadian-time restricted nifedipine administration. Methods Find Exp Clin Pharmacol. 1992;14(9):677-90.
[103]Chickering J, Sowka S, Lamers W, Gonyon R. The use of a fully automated robot for the preparation of plasma and standards for a liquid chromatographic method for diltiazem and its metabolites. J Chromatogr. 1991;568(2):471-80.
[104]Sankar V, Trivedi D, et al. A comparative evaluation of antihypertensive efficacy of diltiazem alone and in combination with atenolol. J Assoc Physicians India. 1993;41(7):432-4.
[105]Luscher TF, Tanner FC, Tschudi MR, Noll G. Endothelial dysfunction in coronary artery disease. Annu Rev Med. 1993;44:395-418.
[106]Nayak UY, Terao D, et al. Glutaraldehyde cross-linked chitosan microspheres for controlled delivery of zidovudine. J Microencapsul. 2009;26(3):214-22.
[107]Ammar HO, Haider M, Ibrahim M, El Hoffy N. In vitro and in vivo investigation for optimization of niosomal ability for sustainment and bioavailability enhancement of diltiazem after nasal administration. Drug Deliv. 2017;24(1):414-21.
[108]Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13(2):123-33.
[109]Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Controlled Release. 2000;63(3):235-59.
[110]Nayak AK, Pal D. Ionotropically-gelled mucoadhesive beads for oral metformin HCl formulation: Development, optimization and antidiabetic evaluation. J Pharm. 2013;2013:Article 378750.
[111]Reddy T, Tammishetti S. Gastric resistant microbeads of metal ion cross-linked carboxymethyl guar gum for oral drug delivery. J Microencapsul. 2002;19(3):311-8.
[112]Singh B, Kumar D, Ahuja N. Optimizing drug delivery systems using systematic 'design of experiments.' Part II: Retrospect and prospects. Crit Rev Ther Drug Carrier Syst. 2005;22(1):27-105.
[113]Morsi N, Ghorab D, Refai H, Teba H. Preparation and evaluation of alginate/chitosan nanocontaining curcumin. Int J Monopharm. 2017;10(3):227-36.
[114]Bodmeier R, Chen H, Paeratakul O. A novel approach to the oral delivery of micro- or nanoparticles. Pharm Res. 1989;6(5):413-7.
[115]Soppimath KS, Aminabhavi TM, Dave AM, Kumbar SG, Rudzinski WE. Stimulus-responsive 'smart' hydrogels as novel drug delivery systems. Drug Dev Ind Pharm. 2002;28(8):957-74.
[116]Sinha VR, Singla AK, Wadhawan S, et al. Chitosan microspheres as a potential carrier for drugs. Int J Pharm. 2004;274(1-2):1-33.
[117]Ray S, Maiti S, Sa B. Polyethyleneimine-treated xanthan beads for prolonged release of diltiazem: In vitro and in vivo evaluation. Arch Pharm Res. 2010;33(4):575-83.
[118]Bari H, et al. Preparation and evaluation of alginate beads by ionotropic gelation method. Int J Pharm Sci Res. 2012;3(7):2096-101.
[119]Bhalerao SS, Lalla JK, Rane MS. A study of electrokinetic and stability property of suspension of diltiazem hydrochloride microcapsule. Indian Drugs. 2001;38:464-7.
[120]Chowdary KP, Ramesh KV. Studies on microencapsulation of diltiazem. Indian J Pharm Sci. 1993;55:52-4.
[121]Reddy MN, Shriwaikar A.A. Rosin: A polymer for microencapsulation of diltiazem hydrochloride for sustained release by emulsion-solvent evaporation technique. Indian J Pharm Sci. 2000;62:308-10.
[122]Kanteti K, et al. Design and evaluation of sustained release gastro retentive floating microsphere of diltiazem HCl. Int J Res Eng Manag Sci. 2017;3(12):1-12.
[123]Kulkarni AD, Bari DB, Surana SJ, Pardeshi CV. In vitro, ex vivo and in vivo performance of chitosan-based spray-dried nasal mucoadhesive microspheres of diltiazem hydrochloride. J Drug Deliv Sci Technol. 2016;31:108-17.
[124]Rao MRP, Borate SG, Thanki KC, et al. Diltiazem-loaded nanosponges for oral sustained delivery. Int J Pharm Investig. 2018;8(4):193-201.
[125]Bolourchian N, Ghorbani M, Mahboubi A, et al. Preparation and evaluation of diltiazem HCl microspheres using Eudragit RL and RS. J Microencapsul. 2007;24(5):475-81.
[126]Arafat M, et al. Formulation and evaluation of sustained release matrix tablets of diltiazem HCl. Int J Pharm Sci Res. 2021;12(3):1524-31.
[127]Joshi P, et al. Development and evaluation of osmotic pump tablets of diltiazem hydrochloride. J Drug Deliv Ther. 2022;12(3):123-9.
[128]Ammar HO, et al. In vitro and in vivo optimization of niosomal diltiazem for nasal delivery. Drug Deliv. 2017;24(1):414-21.
[129]Das S, Ng WK, Tan RB. Are the current CPW processes truly continuous? Pharm Technol. 2012;36(1):52-7.
[130]Rao MRP, et al. Diltiazem-loaded nanosponges for oral sustained delivery. Int J Pharm Investig. 2018;8(4):193-201.
[131]Ivanova NA, Trapani A, Di Franco C, et al. In vitro and ex vivo studies on diltiazem hydrochloride-loaded microsponges in rectal gels for chronic anal fissures treatment. J Drug Deliv Sci Technol. 2025;93:105-19.
[132]Priyadarshini Samanta A, Ghosh A, Dutta K, et al. Biofabrication of aminated nanocellulose reinforced polyvinyl alcohol/chitosan nanofibrous scaffold for sustained release of diltiazem hydrochloride. Mater Sci Eng C. 2024;152:112-25.
[133]Seyedian M, et al. PVA nanofibrous mats containing diltiazem for wound dressing. Int J Biol Macromol. 2023;234:123-32.
[134]Etemadi N, Mehdikhani M, Huri PY, et al. Novel electrospun polyvinyl alcohol/chitosan/polycaprolactone-diltiazem hydrochloride nanocomposite membranes for wound dressing applications. Emergent Mater. 2024;7:1103-13.

[135]Khairnar G, Mokale V, Mujumdar A, Naik J. Development of nanoparticulate sustained release oral drug delivery system for the antihyperglycemic with antihypertensive drug. Mater Technol. 2019;34:880-8.
[136]Sista S, et al. Pharmacokinetics of a novel diltiazem HCl extended-release tablet formulation for evening administration. J Clin Pharmacol. 2003;43(10):1149-57.
[137]Taha EI, Emara LH. In vitro–in vivo correlation and comparative bioavailability studies of diltiazem HCl extended-release tablets. J Pharm Sci. 2022;111(5):1342-50.
[138]Ge X, Wei M, He S, Yuan WE. Advances of non-ionic surfactant vesicles (niosomes) and their application in drug delivery. Pharmaceutics. 2019;11(2):55.
[139]Pandey P, et al. Advancement and characteristics of non-ionic surfactant vesicles (niosome) and their application for analgesics. Int J Pharm Investig. 2024;14(3):616-32.
[140]Utzeri G, et al. Cyclodextrin-based nanosponges: synthesis, properties and applications. Int J Pharm. 2022;623:121-35.
[141]Rao MRP, et al. Diltiazem-loaded nanosponges for oral sustained delivery. Int J Pharm Investig. 2018;8(4):193-201.